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Abstract
Surgical excision was once considered the mainstay
of treatment for lymphangiomas. However, that paradigm is
now changing with sclerotherapy emerging as a viable
alternative. A 22 years old girl presented with a
mucopurulent and painful discharge from an extensive
wound in the trunk. Chest roentogram showed a large soft
tissue abnormality with multiple calcifications in the right
upper abdomen and lower thorax. Magnetic resonance
imaging revealed an extensive lobulated mass measuring 27
x 19 cm. Due to the extensive involvement of tissues,
surgical excision did not appear to be a favourable option in
this case. Local injections of bleomycin were successfully
administered; resulting in complete regression of the lesion.
There has been no recurrence at 2 years of follow up. Use of
bleomycin sclerotherapy appears to be a safe and effective
management strategy and obviates the need for primary
surgery especially in extensive lymphangiomas. 
Introduction
Lymphangiomas are benign and uncommon
hamartomatous malformations of the lymphatic system that
occur secondary to intrauterine obstruction or
developmental arrest.1 Surgical excision was once
considered the mainstay of treatment for lymphangiomas.2
However, sclerotherapy has now come to the forefront as a
viable alternative. This technique obviates the need for
primary surgery and is an effective, safe and minimally
invasive option on its own with minimal complications.3
We describe here a case of a giant lymphangioma of
the trunk that was successfully treated by intra-tumorous
bleomycin injections leading to a complete resolution of the
lesion.
Case Report
A 22 years old girl presented to our hospital with a
mucopurulent, bloody and painful discharge from an
extensive wound in the trunk (Figure-1). On further inquiry,
it was revealed that she had visible dilated cutaneous vessels
since the time of birth that had gradually increased in size
with time. There was no fever or other relevant clinical
findings. She had severe pain at the wound site and various
analgesics had proven to be ineffective in controlling the
pain. She was very hesitant in getting admitted or consulting
any surgeon for this cosmetically debilitating problem;
hence she presented late and her wound was already
infected at the time of presentation. She was also very shy
regarding discussion of her condition. 
Chest roentogram showed a soft tissue abnormality
with multiple calcifications in the right upper abdomen and
lower thorax with a deformity of adjacent right-sided lower
ribs. Magnetic resonance imaging (MRI) revealed a huge
lobulated mass measuring 27 x 19 cm. It was wrapped
around the right half of the trunk with a crescentric
appearance on axial sections (Figure-2). The soft tissues of
the right chest and abdominal wall were replaced by the
mass, which extended from the level of anterior aspect of
the liver till the kidney. Sedimentation in the dependant
portion of the mass was also seen. This appearance was
most consistent with a diagnosis of extensive
lymphangioma of the trunk. 
Due to the extensive nature of the lesion, surgical
management was not a favorable option for this patient. She
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Figure-1: Extensive lymphangioma visible on the trunk of the patient.
was, therefore, treated with local injections of bleomycin
emulsion in almond oil. The patient received bleomycin in
a series of eight sessions, spaced at one month intervals. In
each session, a total of 1 gram of bleomycin was injected
into the four quadrants of the lesion. This treatment strategy
proved highly successful as the lesion completely regressed.
After the complete resolution of the lesion, the patient felt
better from the psychological aspect as well and expressed
greater confidence. 
Discussion
Lymphangiomas are benign lesions of vascular
origin that can virtually involve any organ or tissue within
the body. However, they have a predilection for sites in the
head and neck region as well as the axilla.4 The diagnosis of
lymphangiomas is much more common in children as
compared to adults. As many as 90% of the tumours are
diagnosed by 2 years.5 On ultrasound, lymphangiomas
generally appear as anechoic cystic masses, but
occasionally debris may result in echogenicity. CT and MRI
scans may further aid in the identification of the lesion and
its extensions. Lymphangiomas should be treated because of
the potential for complications such as septic necrosis or
haemorrhage. Other complications depend on the location
of the mass. Abdominal lesions, for instance, can cause
obstruction or peritonitis and manifest as acute abdomen.6
Mediastinal or cervical lesions can cause respiratory
distress.7 Other reasons for treatment may include a
cosmetic improvement. 
Review of local literature didn't show any prior
reports with the use of intra-tumour injections of bleomycin
for the treatment of lymphangiomas. Available reports
included cases of vulval lymphangioma and cavernous
transverse mesocolon lymphangioma.8,9 Surgical resection
was undertaken for the removal of the lesion.9
Lymphangiomas tend to extensively infiltrate the
surrounding tissues. This characteristic makes surgical
excision technically challenging. Radical extirpation may
be undertaken to reduce the recurrence rate.2 However, such
an approach poses risks of injury to surrounding structures
such as nerves or vessels. In recent years, sclerotherapy has
gained more popularity for treating lymphangiomas because
of its safer profile. Two agents that are employed for the
purpose of sclerotherapy are bleomycin and OK-432
(picibanil). Bleomycin therapy has not been associated with
any major side effects so far. Vomiting and local reactions
have been reported to be rare associations of bleomycin
sclerotherapy.10
In a prospective study including 9 patients with
lymphangiomas, ultrasonography was used to delineate the
size, location, nature, and number of compartments of the
cyst prior to the injection. Under ultrasound guidance, the
content of the cystic cavity was aspirated and 1 - 3 mg/kg
bleomycin was injected. In six patients, the mass
disappeared completely after a single injection. In one
patient a second injection was needed, and surgical excision
had to be performed in the remaining two patients.3 This
shows that ultrasonographic guidance can be used to inject
bleomycin into the cystic lesion when technically difficulty
is expected. We used bleomycin emulsified in almond oil,
and ultrasonographic guidance was not used since the
tumour was quite extensive and easily accessible. 
Recurrence, however, can occur with either
approach. This is because lymphangiomas can be difficult to
completely resect surgically or with sclerotherapy
especially if it is extensively involving the surrounding
tissues. A study with the use of bleomycin sclerotherapy for
the management of lymphangiomas has reported a
recurrence rate of 10.3%.10 Despite the extensive
involvement of lymphangioma in our patient, 100%
regression was achieved and there has been no recurrence at
2 years follow-up. 
Apart from bleomycin, other sclerosing agents have
also been used to treat lymphangiomas. In a clinical trial on
the treatment of lymphangiomas in the paediatric
population, OK-432 (Picibanil) was found to be as effective
as bleomycin.11 More studies are, however, needed to
completely elucidate the sclerosing effect of bleomycin in
comparison with other agents. 
Conclusion
We have described a case of a giant lymphangioma
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Figure-2: MRI scan showing a large mass in the right half of the trunk.
of the trunk that was managed without surgical intervention.
Bleomycin sclerotherapy appears to be a useful addition to
the once limited armamentarium for the treatment of
lymphangiomas. Our case showed a dramatic resolution of
the large lesion following bleomycin injections. 
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